Moving From Everyday Dosing to Less Frequent Dosing is Obvious

Feb 3, 2017

Reading Time : 2 min

Plaintiffs were the holders of a New Drug Application for the administration of 40 mg/ml glatiramer acetate (GA) three times per week to treat patients with relapsing forms of multiple sclerosis. They marketed their product under the brand name COPAXONE®. Plaintiffs filed suit alleging patent infringement after several defendants submitted Abbreviated New Drug Applications seeking approval to market generic versions of COPAXONE®. After conducting a seven-day bench trial, the court held that all of the asserted patent claims were invalid as obvious.

In conducting its analysis, the court explained that obviousness “hinges on the core elements of the asserted claims: (1) a 40 mg dose of GA that is (2) administered in three subcutaneous injections over seven days with at least one day between injections.” Regarding the first element, the court found that a 40 mg dosage form of GA was explicitly disclosed in the prior art and that the prior art did not teach away from that dose. For the second element, the court noted that persons of skill in the art knew that daily GA injections were difficult to tolerate and would have been motivated to pursue less frequent dosing schedules. The court also found that the prior art taught that GA administered every other day may be as effective as daily administration. The court ultimately held that the claimed 40 mg dose amount and dosing schedule would have been “obvious to try” because “[t]he 40 mg dose…was one of two doses studied extensively” in the prior art and that “[t]here were also a finite number of days on which to administer injections considering there are only seven days in a week.” The court also considered long-felt need, failure of others, unexpected results and commercial success, but determined that none of these secondary considerations warrant a finding of nonobviousness. As to commercial success, the court acknowledged that, while there is no dispute that COPAXONE® is a successful drug, its success was due to “aggressive pricing, promotion, and COPAXONE® brand loyalty.” The Court’s finding with respect to dosing schedule is consistent with recent precedent holding that claims directed to a once-daily treatment, as opposed to a more frequent schedule, would have been obvious. See AstraZeneca LP v. Breath Ltd., 542 Fed. Appx. 971 at 979-81 (Fed. Cir. 2013); see also Purdue Pharma Prods. L.P. v. Par Pharm. Inc., 377 Fed. Appx. 978 at 982-83 (Fed. Cir. 2010).

In re Copaxone Consolidated Cases, 14-cv-01171 (D. Del. Jan. 30, 2017)

Share This Insight

Previous Entries

IP Newsflash

November 5, 2024

The Federal Circuit vacated a district court’s fee award because the district court considered certain information that was not relevant to the question of whether plaintiff’s case was exceptional. Specifically, the Federal Circuit held that only those “red flags” that related to the successful Section 101 defense, which served as the basis for the district court’s grant of summary judgment, could be used to show the case was fatally flawed.   

...

Read More

IP Newsflash

November 1, 2024

The Federal Circuit’s decision in Kyocera Senco Industrial Tools Inc. v. International Trade Commission articulated a bright-line test for patent expert admissibility: to testify from the perspective of a “person of ordinary skill in the art” (POSITA), the expert must at least meet the definition of a POSITA for the patents-in-suit. Absent that level of skill, Kyocera holds that the witness’s testimony is not sufficiently reliable or relevant enough to be relied on by a fact-finder.

...

Read More

IP Newsflash

October 29, 2024

The PTAB denied a petitioner’s motion to compel routine discovery that sought information from a parallel ITC investigation for alleged inconsistent positions taken by patent owner in the IPR. The board found that patent owner had not taken inconsistent positions but warned patent owner that it had an ongoing duty to produce any information inconsistent with arguments made during the present IPR, even if that information related to arguments patent owner had dropped at the ITC.

...

Read More

IP Newsflash

October 11, 2024

The Central District of California ruled that the heightened pleading standard of Federal Rule of Civil Procedure 9(b) applies to all three prongs of a false patent marking claim, including the third prong, competitive injury. In doing so, took a clear stand on an issue with a nationwide split among district courts.

...

Read More

IP Newsflash

October 10, 2024

In a patent case containing a variety of federal and state law claims, the District of Massachusetts retained supplemental jurisdiction over the state law claims even after all the federal law claims were dismissed.

...

Read More

IP Newsflash

October 3, 2024

The Federal Circuit recently upheld the USPTO’s authority under the estoppel provision 37 C.F.R. § 42.73(d)(3)(i) to prohibit a patent owner from obtaining patent claims that are not patentably distinct from claims previously declared unpatentable in inter partes review (IPR) proceedings. However, the court clarified that the regulation applies only to new claims or amended claims, not previously issued claims.

...

Read More

IP Newsflash

September 27, 2024

In Kyocera Senco Industrial Tools Inc. v. International Trade Commission, the Federal Circuit held that an expert must meet the definition of a “person of ordinary skill in the art” of the asserted patents in order to opine on infringement, among other issues. This new bright-line test and the underlying rationale, however, raised several new questions regarding expert admissibility. SeeFederal Circuit: Narrow Definition of Skill in the Art Dooms Expert’s Testimony” and “Grappling With A Bright-Line Patent Expert Admissibility Test.” The Federal Circuit recently addressed one of those questions, namely whether an expert must have acquired the requisite level of skill as of the time of the invention or whether it is sufficient for an expert to acquire that knowledge at a later date.

...

Read More

IP Newsflash

September 23, 2024

The Director of the USPTO initiated sua sponte review of a PTAB panel’s decision to impose sanctions based on patentee’s conduct during IPR proceedings. The PTAB cancelled all of patentee’s claims, including those not unpatentable on the merits, after finding that patentee deliberately withheld data relevant to the patentability of the claims at issue. In her review, the Director addressed which regulations are implicated upon a party’s misconduct during AIA proceedings and addressed whether entry of judgment in the trial was an appropriate sanction.

...

Read More

© 2024 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.